US OptionsDetailed Quotes
THTX241220C2500
- 0.10
- 0.000.00%
15min DelayClose Nov 26 16:00 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume140 Open Interest2.50Strike Price0.00Turnover281.61%IV113.11%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.2606Delta0.3721Gamma12.20Leverage Ratio-0.0060Theta0.0001Rho3.18Eff Leverage0.0010Vega
Theratechnologies Stock Discussion
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) presented data at IDWeek 2024 highlighting the impact of excess visceral abdominal fat (EVAF) on cardiovascular disease (CVD) risk in people with HIV (PWH). Two studies were presented:
1. The VAMOS study showed that EVAF is prevalent (58%) in PWH on modern anti-r...
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
• Q3 revenue of $22.6 million represents +8% growth year-over-year
• Positive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million
• Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million
NEWS
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
The study highlighted a uni...
NEWS
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
05/02/2024 - 04:30 AM
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors
Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the...
$Heron Therapeutics (HRTX.US)$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia (LQDA.US)$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies (THTX.US)$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
4 MINUTES AGO, 7:00 AM EST
MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received correspondence from the U.S. Food and Drug Administration (FDA) regarding the Company's supplemental Biolo...
No comment yet